Orion Pharma Ltd.

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS1 APRIL 2026 at 16.00 EEST Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines Orion Corporation (“Orion”) has appointed Berkeley Vincent as Executive Vice President, Innovative Medicines and a member of the Orion Executive Team as of 8 April 2026. The appointment is part of a leadership structure change in which the previously combined role of R&D and Innovative Medicines is split into two dedicated positions. This change reflects the continued growth and maturation of Orion’s Innovative Medicines pipeline and the increasing need to strengthen focus on global commercialization readiness. Outi Vaarala will continue in her role as Executive Vice President, R&D, and as a member of the Orion Executive Team. In his new role, Berkeley Vincent will be responsible for defining and implementing global commercialization strategies for Orion’s Innovative Medicines portfolio. His responsibilities include full P&L ownership, global launch sequencing, market access strategy, and the development of strategic partnerships, including licensing and acquisitions. He will work closely with R&D leadership to align development priorities with commercial and market needs. Berkeley Vincent brings more than 20 years of international pharmaceutical industry experience from senior global, regional and country leadership roles at Johnson & Johnson. Most recently, he served as President, Johnson & Johnson Innovative Medicines Canada, with full P&L responsibility. He has previously held roles including Managing Director of the Nordic cluster and Global Commercial Leader for IMBRUVICA. Berkeley Vincent will be based in Finland and will report to Orion’s President and CEO, Liisa Hurme. ANNEX: CV of Berkeley Vincent Berkeley VincentBorn 1977Irish and Swedish citizen Education:MBA, DePaul University, Chicago, 2002BSc (Management), Trinity College Dublin, 1999 Career:2022– President, Johnson & Johnson Canada2019–2022  Nordics Managing Director, Johnson & Johnson 2018–2019  Vice President, Customer Digital Strategy, Johnson & Johnson, EMEA2015–2018  Regional Strategy Leader, Johnson & Johnson, EMEA2012–2015  Global Commercial Leader IMBRUVICA, Johnson & Johnson2002–2012  Various commercial and leadership roles, Johnson & Johnson Orion Corporation Liisa HurmePresident and CEO Contact person:Terhi Ormio, Vice President, Communicationstel. +358 50 966 4646 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orionpharma.com Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being. Attachment Berkeley Vincent

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS20 March 2026 at 15.40 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 19 March 2026 below five (5) per cent of Orion Corporation’s total shares. Total positions of BlackRock, Inc. and its funds subject to notification: % of shares and voting rights (total of point A)% of shares and voting rights through financial instruments (total of point B)Total of both in % (points A + B)Total number of shares and voting rights of issuerResulting situation on the date on which threshold was crossed or reachedBelow 5% shares Below 5% voting rightsBelow 5% shares Below 5% voting rightsBelow 5% shares Below 5% voting rights141,134,278 shares 740,104,338 voting rightsPosition of previous notification (if applicable)5.02% shares Below 5% voting rights0.00% shares Below 5% voting rights5.02% shares Below 5% voting rights Notified details of the resulting situation on the date on which the threshold was crossed: Point A: Shares and voting rights: Class/type of sharesISIN codeNumber of shares and voting rights% of shares and voting rights Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)Direct (SMA 9:5)Indirect (SMA 9:6 and 9:7)FI0009014377 Below 5% shares Below 5% voting rights Below 5% shares Below 5% voting rightsPOINT A SUBTOTALBelow 5% shares Below 5% voting rightsBelow 5% shares Below 5% voting rights Point B: Financial instruments according to SMA 9:6a: Type of financial instrumentExpiration dateExercise / Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rightsAmerican Depositary Receipt (US68628Y1047)N/AN/APhysicalBelow 5% shares Below 5% voting rightsBelow 5% shares Below 5% voting rightsCFDN/AN/ACashBelow 5% shares Below 5% voting rightsBelow 5% shares Below 5% voting rights POINT B SUBTOTALBelow 5% shares Below 5% voting rightsBelow 5% shares Below 5% voting rights Orion Corporation Liisa HurmePresident and CEO Mikko KemppainenGeneral Counsel Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporationtel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orionpharma.com Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.

Sweden-based biopharma AnaCardio AB, which focuses on development of contractile agents for heart failure, and Switzerland-based partner Helsinn Healthcare SA announced the issuance of US Patent No. 12,569,476 by the United States Patent and Trademark Office (USPTO). The patent covers the use of AC01, a first-in-class calcium sensitizing inotrope and oral ghrelin mimetic small molecule, for the treatment of heart failure with reduced ejection fraction (HFrEF). This dual mechanism targets cardiac contractile dysfunction through enhanced myofilament calcium sensitivity while simultaneously engaging the ghrelin receptor pathway, which has been linked to cardioprotective and metabolic effects in failing hearts. AnaCardio US patent extends AC01 exclusivity into the 2040s The biopharmaceutical patent provides protection in the United States until June 2, 2042, with potential patent term extensions beyond that date. The patent is co-owned by AnaCardio AB and Helsinn Healthcare SA. The Helsinn Healthcare AnaCardio partnership, which originated with Helsinn’s out-licensing of the compound to AnaCardio, now benefits from what the companies describe as a layered intellectual property position supporting AC01 well into the 2040s. AC01 contractile agent: mechanism and clinical development AC01 functions through two pharmacological pathways. As a calcium sensitizer, the AC01 contractile agent increases the responsiveness of cardiac myofilaments to intracellular calcium, improving the force of heart contractions without raising intracellular calcium concentrations. This distinction is relevant because traditional inotropes that increase calcium influx carry risks of arrhythmia and elevated myocardial oxygen demand. As an oral ghrelin mimetic, AC01 activates the growth hormone secretagogue receptor (GHS-R1a), which is expressed in cardiovascular tissue. Ghrelin receptor activation has been associated with anti-apoptotic signaling, improved cardiac remodeling, and metabolic regulation in preclinical heart failure models. The combination of these two mechanisms in a single oral small molecule differentiates AC01 from existing agents in the HFrEF treatment landscape. AnaCardio completed a Phase Ib/IIa trial (NCT information via AnaCardio pipeline) enrolling 58 patients with HFrEF across sites in Italy and the Netherlands. The company disclosed positive topline results, reporting that AC01 demonstrated a favorable safety and tolerability profile alongside exploratory efficacy signals described as rapid and sustained improvements in cardiac function and hemodynamics over 28 days. A second study enrolling 62 patients across the United Kingdom, Italy, and Sweden (trial record) has also been conducted. As of late 2025, AnaCardio stated plans to advance AC01 into Phase IIb development. Specific clinical results for individual endpoints and detailed adverse event data have not yet appeared in peer-reviewed publications. The AC01 heart failure treatment enters a field with several mechanistically relevant comparators. Levosimendan, marketed by Orion Pharma (Finland), is the most established calcium sensitizer in clinical use. Approved in multiple countries for acute decompensated heart failure, levosimendan enhances myofilament calcium sensitivity and produces vasodilation through potassium channel activation. It is administered intravenously, and ongoing trials are evaluating repetitive infusion regimens in advanced chronic heart failure (NCT record). AC01’s oral formulation and dual mechanism represent a differentiation strategy relative to levosimendan’s IV-only route and single-pathway activity. Omecamtiv mecarbil, developed by Cytokinetics (US) in partnership with Amgen (US), operates through a distinct contractility mechanism as a cardiac myosin activator. Rather than sensitizing myofilaments to calcium, it directly targets cardiac myosin ATPase to increase the duration and magnitude of systolic contraction. Omecamtiv mecarbil completed the Phase III GALACTIC-HF trial (NCT01920711), but a US FDA approval filing was met with a complete response letter in February 2023. Its mechanism does not overlap with ghrelin signaling, distinguishing it from AC01’s pharmacological profile. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website